查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1916705

全球人工智慧诊断市场：未来预测（至2032年）－按组件、类型、技术、应用、最终用户和地区进行分析

AI Diagnostics Market Forecasts to 2032 - Global Analysis By Component (Software, Hardware and Services), Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的一项研究，预计到 2025 年，全球人工智慧诊断市场价值将达到 74.8 亿美元，到 2032 年将达到 1028.7 亿美元，在预测期内的复合年增长率为 45.4%。

人工智慧诊断是指应用人工智慧技术，例如机器学习、深度学习和数据分析，来辅助检测、分析和解读疾病。人工智慧系统能够处理大量的患者数据、医学影像和临床记录，以高精度和高速度识别疾病模式和异常情况，从而辅助临床医生进行决策。这些工具有助于疾病的早期发现，提高诊断准确率，减少人为错误，并优化治疗方案。人工智慧诊断涵盖放射学、病理学、心臟病学和基因组学等多个领域，正在将传统的医疗实践转变为更有效率、数据驱动且更具预测性的方法。

将巨量资料整合到医疗保健领域

巨量资料在医疗保健领域的应用是推动人工智慧诊断市场发展的主要因素。透过利用源自电子健康记录、医学影像和基因组图谱的大量资料集，人工智慧系统能够提供精准的洞察、预测分析和个人化的治疗建议。这种能力提高了临床决策的准确性，提升了营运效率，并加快了疾病检测速度。人工智慧与巨量资料的融合使医疗服务提供者能够识别以往未曾发现的模式和趋势，从而推动了全球范围内人工智慧诊断技术的普及和市场成长。

高昂的实施成本

高昂的实施成本仍然是人工智慧诊断市场的主要阻碍因素。部署人工智慧解决方案需要对硬体、软体和专业人员进行大量投资，并且还需要持续的系统维护和更新。小规模的医疗机构和新兴市场可能面临实施方面的财务障碍。此外，与现有医疗基础设施整合以及遵守资料安全标准也会增加成本。这些财务和营运方面的挑战可能会减缓市场渗透速度，并限制其广泛应用，尤其是在资源匮乏的地区。

政府主导的政策和投资

政府的各项措施和投资为市场带来了巨大的机会。扶持性政策、资助计画和伙伴关係将鼓励人工智慧医疗解决方案的研究、开发和应用。鼓励医院采用数位化医疗技术和整合人工智慧的奖励将加速创新并扩大医疗服务的可近性。这些措施将有助于克服基础设施和成本方面的挑战，从而促进市场成长。加强公私合营和政府支持的先导计画将增强信任，并为人工智慧诊断技术的广泛应用铺平道路，使其惠及从新兴经济体到先进医疗体系的各个层面。

监理不确定性

监管的不确定性对市场构成重大威胁。核准流程、合规标准和资料隐私法规的不断变化可能会延缓人工智慧技术的部署和商业化。不同地区医疗保健领域人工智慧法律体制的差异，也使全球推广应用变得更加复杂。责任认定和演算法透明度方面的模糊性可能会抑制投资并减缓创新。企业必须在复杂的法规环境运作，以确保安全性、有效性和合乎伦理的使用，而监管的不确定性则持续为市场稳定带来挑战。

新冠疫情的感染疾病：

新冠疫情加速了人工智慧诊断技术的应用，并凸显了其在应对大规模医疗挑战方面的潜力。人工智慧能够快速分析医学影像和患者数据，并预测感染趋势。远距离诊断和远端保健解决方案迅速普及，有助于减轻医疗机构的压力，提高临床效率。然而，疫情也扰乱了供应链，延缓了部分部署，并暂时转移了投资方向。整体而言，新冠疫情既是疫情应对和未来医疗韧性发展的催化剂，也是挑战。

预计在预测期内，机器学习领域将占据最大的市场份额。

预计在预测期内，机器学习领域将占据最大的市场份额，因为系统能够从历史患者数据、医学影像和临床结果中学习，从而不断提高诊断准确率。这项功能有助于疾病的早期检测、预测建模和个人化治疗方案的发展。其在包括放射学和病理学在内的多个专科领域的适用性，使其成为医疗服务提供者极具价值的技术。先进演算法的日益普及及其与巨量资料分析的融合，将确保机器学习解决方案的持续成长和市场主导地位。

预计在预测期内，肿瘤治疗领域将达到最高的复合年增长率。

预计在预测期内，肿瘤学领域将实现最高成长率，因为人工智慧技术透过先进的成像、基因组分析和预测建模，促进了癌症的早期检测和治疗方案的发展。癌症发生率的上升以及对精准化和个人化治疗方法的需求，正在推动肿瘤诊断技术的应用。人工智慧提高了识别恶性肿瘤和预测疾病进展的准确性，从而辅助临床医生进行决策。对人工智慧肿瘤解决方案的持续创新和投资，正在推动该领域的显着成长。

占比最大的地区：

由于数位化加快以及人们对人工智慧解决方案的认知度不断提高，预计亚太地区将在预测期内占据最大的市场份额。医院基础设施的扩建、慢性病盛行率的上升以及政府鼓励采用数位医疗的倡议将进一步推动市场成长。此外，技术提供者与医疗机构之间的合作正使人工智慧诊断更加普及和整合。亚太地区人口密度高，加上医疗保健支出不断增长，将使其成为全球市场扩张的主要驱动力。

年复合成长率最高的地区：

预计北美地区在预测期内将实现最高的复合年增长率，这得益于其强大的技术基础设施和对人工智慧驱动解决方案的早期应用。政府的支持性政策、大量的私人投资以及主要人工智慧医疗公司的入驻正在加速创新。先进的研究倡议、大规模临床数据的获取以及患者的高度认知进一步增强了市场动态。这些因素的综合作用将使北美实现显着成长，并保持其在全球人工智慧诊断应用领域的主导地位。

免费客製化服务：

订阅本报告的用户可从以下免费自订选项中选择一项：

  • 公司简介
    • 对最多三家其他公司进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家进行市场估算、预测和复合年增长率分析（註：基于可行性检查）
  • 竞争标竿分析
    • 基于产品系列、地域覆盖和策略联盟对主要企业进行基准分析

目录

第一章执行摘要

第二章 引言

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
  • 分析材料

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代产品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

第五章 全球人工智慧诊断市场（按组件划分）

  • 软体
  • 硬体
  • 服务

第六章 全球人工智慧诊断市场（按类型划分）

  • 体外诊断
  • 影像诊断
  • 其他类型

第七章 全球人工智慧诊断市场（按技术划分）

  • 机器学习
  • 深度学习
  • 自然语言处理
  • 电脑视觉

第八章 全球人工智慧诊断市场（按应用划分）

  • 放射学和诊断影像
  • 病理
  • 心臟病
  • 瘤
  • 神经系统疾病
  • 其他用途

第九章 全球人工智慧诊断市场（按最终用户划分）

  • 医院
  • 诊断检查室
  • 诊断影像中心
  • 其他最终用户

第十章 全球人工智慧诊断市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章：主要趋势

  • 合约、商业伙伴关係和合资企业
  • 企业合併（M&A）
  • 新产品上市
  • 业务拓展
  • 其他关键策略

第十二章：公司简介

  • GE HealthCare
  • Digital Diagnostics Inc.
  • Koninklijke Philips NV
  • Tempus AI, Inc.
  • Microsoft Corporation
  • Qure.ai
  • Google LLC
  • Zebra Medical Vision
  • NVIDIA Corporation
  • Ibex Medical Analytics
  • IBM Corporation
  • Lunit Inc.
  • Aidoc Medical Ltd
  • Siemens Healthineers AG
  • PathAI, Inc.
Product Code: SMRC33278

According to Stratistics MRC, the Global AI Diagnostics Market is accounted for $7.48 billion in 2025 and is expected to reach $102.87 billion by 2032 growing at a CAGR of 45.4% during the forecast period. AI Diagnostics refers to the application of artificial intelligence technologies, including machine learning, deep learning, and data analytics, to assist in the detection, analysis, and interpretation of medical conditions. By processing vast amounts of patient data, medical images, and clinical records, AI systems can identify patterns and anomalies with high accuracy and speed, supporting clinicians in decision-making. These tools enhance early disease detection, improve diagnostic precision, reduce human error, and optimize treatment planning. AI diagnostics spans multiple areas, including radiology, pathology, cardiology, and genomics, transforming traditional healthcare practices into more efficient, data-driven, and predictive approaches.

Market Dynamics:

Driver:

Integration of Big Data in Healthcare

The integration of big data in healthcare is a primary driver for the AI diagnostics market. Leveraging massive datasets from electronic health records, medical imaging, and genomic profiles, AI systems can deliver precise insights, predictive analytics, and personalized treatment recommendations. This capability improves clinical decision-making, enhances operational efficiency, and accelerates disease detection. The convergence of AI and big data enables healthcare providers to identify patterns and trends that were previously inaccessible, driving adoption and market growth globally.

Restraint:

High Implementation Costs

High implementation costs remain a significant restraint for the AI diagnostics market. Deploying AI solutions requires substantial investment in hardware, software, and skilled personnel, along with continuous system maintenance and updates. Smaller healthcare facilities and emerging markets may face financial barriers to adoption. Additionally, integration with existing medical infrastructure and compliance with data security standards adds to the expense. These financial and operational challenges can slow market penetration, particularly in resource-limited regions, restricting widespread adoption.

Opportunity:

Government Initiatives & Investments

Government initiatives and investments present a major opportunity for the market. Supportive policies, funding programs, and partnerships encourage research, development, and deployment of AI-powered healthcare solutions. Incentives for digital health adoption and AI integration in hospitals accelerate innovation and expand accessibility. Such efforts help overcome infrastructure and cost challenges, fostering market growth. Increased public-private collaborations and government-backed pilot projects promote trust, and open avenues for AI diagnostics across emerging economies and developed healthcare systems.

Threat:

Regulatory Uncertainty

Regulatory uncertainty poses a notable threat to the market. The evolving landscape of approvals, compliance standards, and data privacy regulations can delay deployment and commercialization of AI technologies. Different regions maintain varying legal frameworks for AI in healthcare, complicating global adoption. Ambiguities around liability and algorithm transparency may deter investment and slow innovation. Companies must navigate complex regulatory environments to ensure safety, efficacy, and ethical use, making regulatory unpredictability a persistent challenge impacting market stability.

Covid-19 Impact:

The Covid-19 pandemic accelerated the adoption of AI diagnostics, highlighting its potential in managing large-scale healthcare challenges. AI enabled rapid analysis of medical images, patient data, and predictive modeling for outbreak trends. Remote diagnostics and telehealth solutions gained prominence, reducing strain on healthcare facilities and enhancing clinical efficiency. However, the pandemic also disrupted supply chains, slowed certain implementations, and temporarily diverted investments. Overall, Covid-19 acted as both a catalyst and a challenge, in pandemic response and future healthcare resilience.

The machine learning segment is expected to be the largest during the forecast period

The machine learning segment is expected to account for the largest market share during the forecast period as it enable systems to learn from historical patient data, medical images, and clinical outcomes, continuously improving diagnostic accuracy. This capability supports early disease detection, predictive modeling, and personalized treatment planning. Its adaptability across multiple specialties, including radiology and pathology, makes it highly valuable for healthcare providers. Increasing adoption of advanced algorithms and integration with big data analytics ensures sustained growth and a leading market share for machine learning solutions.

The oncology segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the oncology segment is predicted to witness the highest growth rate, as AI technologies facilitate early cancer detection and treatment planning through advanced imaging, genomic analysis, and predictive modeling. The rising prevalence of cancer, coupled with demand for precise and personalized therapies, drives adoption in oncology diagnostics. AI enhances accuracy in identifying malignancies and predicting disease progression, supporting clinicians in decision-making. Continuous innovations and investments in AI-powered oncology solutions position this segment for significant growth.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to rapid digitization, and growing awareness of AI solutions. Expanding hospital infrastructure, rising chronic disease prevalence and government initiatives promoting digital health adoption further drives market growth. Additionally, collaboration between technology providers and healthcare institutions enhances accessibility and integration of AI diagnostics. A combination of high population density and increasing healthcare expenditure positions Asia Pacific as a key contributor to global market expansion.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to Strong technological infrastructure and early adoption of AI-driven solutions contribute to rapid growth. Supportive government policies, substantial private investments, and the presence of major AI healthcare companies accelerate innovation. Advanced research initiatives, access to large-scale clinical data, and high patient awareness further strengthen market dynamics. These factors collectively enable North America to achieve significant growth and maintain a leadership position in AI diagnostics adoption globally.

Key players in the market

Some of the key players in AI Diagnostics Market include GE HealthCare, Digital Diagnostics Inc., Koninklijke Philips N.V., Tempus AI, Inc., Microsoft Corporation, Qure.ai, Google LLC, Zebra Medical Vision, NVIDIA Corporation, Ibex Medical Analytics, IBM Corporation, Lunit Inc., Aidoc Medical Ltd, Siemens Healthineers AG, and PathAI, Inc.,

Key Developments:

In November 2025, Siemens Healthineers introduced Syngo Carbon 2.0, an upgraded enterprise imaging platform. The launch integrates multimodal imaging data, AI-powered workflow automation, and cloud-based collaboration, designed to streamline radiology operations and improve diagnostic accuracy across global healthcare systems.

In October 2025, Siemens Healthineers expanded its collaboration with Varian and multiple oncology centers to accelerate precision therapy solutions. The joint venture integrates imaging, radiation therapy, and AI-driven planning tools, aiming to improve cancer treatment outcomes and strengthen Siemens' leadership in oncology care.

Components Covered:

  • Software
  • Hardware
  • Services

Types Covered:

  • In Vitro Diagnostics
  • Diagnostic Imaging
  • Other Types

Technologies Covered:

  • Machine Learning
  • Deep Learning
  • Natural Language Processing
  • Computer Vision

Applications Covered:

  • Radiology & Imaging
  • Pathology
  • Cardiology
  • Oncology
  • Neurology
  • Other Applications

End Users Covered:

  • Hospitals
  • Diagnostic Laboratories
  • Diagnostic Imaging Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global AI Diagnostics Market, By Component

  • 5.1 Introduction
  • 5.2 Software
  • 5.3 Hardware
  • 5.4 Services

6 Global AI Diagnostics Market, By Type

  • 6.1 Introduction
  • 6.2 In Vitro Diagnostics
  • 6.3 Diagnostic Imaging
  • 6.4 Other Types

7 Global AI Diagnostics Market, By Technology

  • 7.1 Introduction
  • 7.2 Machine Learning
  • 7.3 Deep Learning
  • 7.4 Natural Language Processing
  • 7.5 Computer Vision

8 Global AI Diagnostics Market, By Application

  • 8.1 Introduction
  • 8.2 Radiology & Imaging
  • 8.3 Pathology
  • 8.4 Cardiology
  • 8.5 Oncology
  • 8.6 Neurology
  • 8.7 Other Applications

9 Global AI Diagnostics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Diagnostic Laboratories
  • 9.4 Diagnostic Imaging Centers
  • 9.5 Other End Users

10 Global AI Diagnostics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 GE HealthCare
  • 12.2 Digital Diagnostics Inc.
  • 12.3 Koninklijke Philips N.V.
  • 12.4 Tempus AI, Inc.
  • 12.5 Microsoft Corporation
  • 12.6 Qure.ai
  • 12.7 Google LLC
  • 12.8 Zebra Medical Vision
  • 12.9 NVIDIA Corporation
  • 12.10 Ibex Medical Analytics
  • 12.11 IBM Corporation
  • 12.12 Lunit Inc.
  • 12.13 Aidoc Medical Ltd
  • 12.14 Siemens Healthineers AG
  • 12.15 PathAI, Inc.

List of Tables

  • Table 1 Global AI Diagnostics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global AI Diagnostics Market Outlook, By Component (2024-2032) ($MN)
  • Table 3 Global AI Diagnostics Market Outlook, By Software (2024-2032) ($MN)
  • Table 4 Global AI Diagnostics Market Outlook, By Hardware (2024-2032) ($MN)
  • Table 5 Global AI Diagnostics Market Outlook, By Services (2024-2032) ($MN)
  • Table 6 Global AI Diagnostics Market Outlook, By Type (2024-2032) ($MN)
  • Table 7 Global AI Diagnostics Market Outlook, By In Vitro Diagnostics (2024-2032) ($MN)
  • Table 8 Global AI Diagnostics Market Outlook, By Diagnostic Imaging (2024-2032) ($MN)
  • Table 9 Global AI Diagnostics Market Outlook, By Other Types (2024-2032) ($MN)
  • Table 10 Global AI Diagnostics Market Outlook, By Technology (2024-2032) ($MN)
  • Table 11 Global AI Diagnostics Market Outlook, By Machine Learning (2024-2032) ($MN)
  • Table 12 Global AI Diagnostics Market Outlook, By Deep Learning (2024-2032) ($MN)
  • Table 13 Global AI Diagnostics Market Outlook, By Natural Language Processing (2024-2032) ($MN)
  • Table 14 Global AI Diagnostics Market Outlook, By Computer Vision (2024-2032) ($MN)
  • Table 15 Global AI Diagnostics Market Outlook, By Application (2024-2032) ($MN)
  • Table 16 Global AI Diagnostics Market Outlook, By Radiology & Imaging (2024-2032) ($MN)
  • Table 17 Global AI Diagnostics Market Outlook, By Pathology (2024-2032) ($MN)
  • Table 18 Global AI Diagnostics Market Outlook, By Cardiology (2024-2032) ($MN)
  • Table 19 Global AI Diagnostics Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 20 Global AI Diagnostics Market Outlook, By Neurology (2024-2032) ($MN)
  • Table 21 Global AI Diagnostics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 22 Global AI Diagnostics Market Outlook, By End User (2024-2032) ($MN)
  • Table 23 Global AI Diagnostics Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 24 Global AI Diagnostics Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 25 Global AI Diagnostics Market Outlook, By Diagnostic Imaging Centers (2024-2032) ($MN)
  • Table 26 Global AI Diagnostics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.